Escape from targeted inhibition: The dark side of kinase inhibitor therapy

Cell Cycle

Volumn 9, Issue 9, 2010, Pages 1661-1662

  Wykosky, Jill ^a   Mukasa, Akitake ^a,b   Furnari, Frank ^a   Cavenee, Webster K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

EDITORIAL; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; LUNG CANCER;

EID: 77953573187     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.9.11592     Document Type: Editorial

References (11)

1. Feld R, et al. J Thorac Oncol 2006; 1:367-76.
2. Rich JN, et al. J Clin Oncol 2004; 22:133-42.
3. Furnari FB, et al. Genes Dev 2007; 21:2683-710.
4. Nagane M, et al. Cancer Res 1996; 56:5079-86.
5. Mukasa A, et al. Proc Natl Acad Sci USA 2010; 107:2616-21.
6. Li J, et al. Cancer Biol Ther 2007; 6:432-8.
7. Stommel JM, et al. Science 2007; 318:287-90.
8. Engelman JA, et al. Science 2007; 316:1039-43.
9. Huang PH, et al. Proc Natl Acad Sci USA 2007; 104:12867-72.
10. Mellinghoff IK, et al. N Engl J Med 2005; 353:2012-24.
11. Kobayashi S, et al. N Engl J Med 2005; 352:786-92.